Expanding the Scope of Base Editing
Expanding the Scope of Base Editing
批准号:
10459380
负责人:
DAVID R LIU
金额:
$42.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-23 至 2024-07-31
关键词:
AddressAdenineBacteriophagesBase PairingBindingBiological SciencesCellsChemicalsClinicClustered Regularly Interspaced Short Palindromic RepeatsCollectionCytidineDNADNA BindingDNA Repair PathwayDeaminationDevelopmentDiscriminationDiseaseEffectivenessEventEvolutionGTP-Binding Protein alpha Subunits, GsGeneticGenetic DiseasesGenetic studyGenomeGenomicsGoalsGuanineHumanIndividualLaboratoriesLeadLettersLocationMediatingMethodsMitoticMutationNatureNucleotidesOrganismPathogenicityPatientsPositioning AttributeProteinsPublicationsPurinesPyrimidinePyrimidinesReportingResearchScienceSiteSomatic CellSpecificityTestingTherapeuticVariantbasebase editingbase editordisease-causing mutationgenome editinghomologous recombinationhuman diseaseimprovedin vivoinnovationnext generationnucleobaseoxidationsuccesstransition mutationtransversion mutation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Expanding the Scope of Base Editing
Genome editing has revolutionized the life sciences and offers the potential to cure genetic diseases. We
recently developed base editing, a method of making single-base changes at target genomic sites without
introducing double-strand breaks or relying on homologous recombination. Base editors (BEs) are especially
relevant for the study and treatment of genetic diseases because the majority of disease-relevant mutations are
single-base changes. In the two years since we pioneered base editing with a C•G-to-T•A editor, we have
improved BE efficiency and product purity, reduced off-target and bystander base editing, evolved a new class
of adenine base editors (ABEs) that convert A•T to G•C base pairs, expanded the targeting scope of BEs,
established base editing of post-mitotic somatic cells in vivo, and applied BEs to record cellular events.
Hundreds of other laboratories around the world have used base editing to study genetic diseases and to test
potential therapeutic strategies. Here we propose to expand the capabilities of base editors towards the
transformative goal of enabling any desired base change at any target locus in any somatic cell.
Base editing requires the presence of an appropriately positioned protospacer adjacent motif (PAM) for
binding of the Cas9 domain. Most DNA sites remain inaccessible for genome editing due to the lack of any
DNA-binding CRISPR protein that recognizes the majority of PAMs. To further expand our ability to base edit
the broadest range of targets, we will use our phage-assisted continuous evolution (PACE) platform to rapidly
evolve a collection of Cas9 variants that recognize currently many untargetable PAM sequences (Aim 1a). The
targeting scope of BEs is also limited by inefficient editing of certain base pairs because of sequence context. To
further expand the targeting scope of base editing, we will use our recently established PACE selection for base
editing to generate BEs that can efficiently modify targets with currently disfavored flanking sequences (Aim 1b).
Base editors modify bases within the editing window, a range of ~5 nucleotides positioned relative to the
PAM. In addition to conversion of the target C•G or A•T base pair, other “bystander” C•G or A•T base pairs are
also edited within this window. These bystander edits can lead to undesired genome changes. To minimize
bystander base editing, we propose to evolve a large set of BEs that will only edit bases within specific
sequence contexts (Aim 2), thereby enabling discrimination between multiple Cs or As within the editing window.
Finally, a major limitation of base editing is the inability to generate transversion (purine ßà pyrimidine)
mutations, which are needed to install or correct ~38% of known human pathogenic SNPs. We propose to
develop the first base editors that can generate transversion mutations at target base pairs using two distinct
strategies (Aims 3a and 3b). Success with either strategy would greatly expand the capabilities of base editing,
and would also allow, in principle, all 12 possible base-to-base change via individual or sequential use of
transition and transversion editors.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1093/nar/gkad1125
发表时间:
2024-01-25
期刊:
Nucleic acids research
影响因子:
14.9
作者:
[]
通讯作者:
Project 3: Therapeutic Gene Editing for Huntington's Disease
-
批准号:10668769
-
项目类别:
-
资助金额:$67.03万
-
财政年份:2023
-
负责人:DAVID R LIU
-
依托单位:
Gene Editing Core
-
批准号:10668765
-
项目类别:
-
资助金额:$40.85万
-
财政年份:2023
-
负责人:DAVID R LIU
-
依托单位:
Project 2: Therapeutic Gene Editing for Friedreich's Ataxia
-
批准号:10668768
-
项目类别:
-
资助金额:$64.66万
-
财政年份:2023
-
负责人:DAVID R LIU
-
依托单位:
Base editing and prime editing for sickle cell disease
-
批准号:10157511
-
项目类别:
-
资助金额:$73.36万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
Continuous Evolution of Proteins with Novel Therapeutic Potential
-
批准号:10181559
-
项目类别:
-
资助金额:$62.19万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
Base editing and prime editing for sickle cell disease
-
批准号:10323054
-
项目类别:
-
资助金额:$71.57万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
Base editing and prime editing for sickle cell disease
-
批准号:10579903
-
项目类别:
-
资助金额:$77.71万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
Continuous Evolution of Proteins with Novel Therapeutic Potential
-
批准号:10588186
-
项目类别:
-
资助金额:$62.19万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
Continuous Evolution of Proteins with Novel Therapeutic Potential
-
批准号:10393666
-
项目类别:
-
资助金额:$62.19万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
PedGeneRx - Admin Supplement to Base Editing and Prime Editing for Sickle Cell Disease R01
-
批准号:10594247
-
项目类别:
-
资助金额:$18.2万
-
财政年份:2021
-
负责人:DAVID R LIU
-
依托单位:
Expanding the Scope of Base Editing
-
批准号:10227955
-
项目类别:
-
资助金额:$42.15万
-
财政年份:2018
-
负责人:DAVID R LIU
-
依托单位:
Expanding the Scope of Base Editing
-
批准号:9982216
-
项目类别:
-
资助金额:$42.18万
-
财政年份:2018
-
负责人:DAVID R LIU
-
依托单位:
Expanding the Scope of Base Editing
-
批准号:9768957
-
项目类别:
-
资助金额:$42.21万
-
财政年份:2018
-
负责人:DAVID R LIU
-
依托单位:
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics
-
批准号:9070238
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2016
-
负责人:DAVID R LIU
-
依托单位:
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics
-
批准号:9258439
-
项目类别:
-
资助金额:$6.96万
-
财政年份:2016
-
负责人:DAVID R LIU
-
依托单位:
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics
-
批准号:10162933
-
项目类别:
-
资助金额:$59.11万
-
财政年份:2016
-
负责人:DAVID R LIU
-
依托单位:
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics
-
批准号:10395607
-
项目类别:
-
资助金额:$59.11万
-
财政年份:2016
-
负责人:DAVID R LIU
-
依托单位:
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics
-
批准号:10610354
-
项目类别:
-
资助金额:$59.11万
-
财政年份:2016
-
负责人:DAVID R LIU
-
依托单位:
New Approaches for the Delivery of Proteins and Nucleic Acids Into Cells
-
批准号:8210848
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2011
-
负责人:DAVID R LIU
-
依托单位:
New Approaches for the Delivery of Proteins and Nucleic Acids Into Cells
-
批准号:8601534
-
项目类别:
-
资助金额:$32.65万
-
财政年份:2011
-
负责人:DAVID R LIU
-
依托单位:
海外基金